导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.85% | 3137/4773 |
| 近一周 | -1.70% | 2585/5465 |
| 近一月 | -4.91% | 3514/5421 |
| 近一季 | -9.76% | 3629/5231 |
| 近半年 | -5.06% | 2983/4920 |
| 近一年 | 2.32% | 2298/4394 |
| 近两年 | 44.54% | 1694/2954 |
| 近三年 | 28.21% | 1161/2253 |
| 成立以来 | 144.42% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.44% 2790/4961 |
12.82% 2113/5312 |
- - |
- - |
| 2025 | 19.36% 2225/4813 |
-0.80% 2413/3635 |
1.43% 2332/4076 |
15.54% 2794/4524 |
2.67% 888/4813 |
| 2024 | 17.58% 676/3463 |
2.26% 801/2808 |
-0.98% 884/3014 |
16.81% 1344/3129 |
-0.59% 1471/3463 |
| 2023 | -6.76% 873/2656 |
5.00% 845/2280 |
-3.62% 846/2385 |
-2.50% 686/2515 |
-5.49% 1371/2655 |
| 2022 | -17.58% 607/2207 |
-13.46% 761/1919 |
7.77% 429/2016 |
-12.81% 787/2113 |
1.36% 1290/2208 |
| 2021 | 3.48% 607/1822 |
-2.46% 648/1255 |
6.52% 739/1330 |
-2.83% 595/1466 |
2.50% 576/1822 |
| 2020 | 43.71% 239/1250 |
-6.78% 509/1028 |
15.15% 513/1067 |
16.61% 143/1164 |
14.81% 246/1184 |
| 2019 | 38.53% 307/1092 |
25.59% 452/754 |
-0.47% 267/804 |
1.80% 355/850 |
8.86% 277/918 |
| 2018 | -22.43% 240/834 |
- - |
- - |
- - |
-10.37% 193/691 |
| 2017 | 19.11% 200/714 |
- - |
- - |
- - |
- - |
| 2016 | -10.61% 284/605 |
- - |
- - |
- - |
- - |
| 2015 | 5.47% 221/575 |
- - |
- - |
- - |
- - |
| 2014 | 49.36% 89/237 |
- - |
- - |
- - |
- - |
| 2013 | -6.22% 112/186 |
- - |
- - |
- - |
- - |
| 2012 | 8.01% 60/140 |
- - |
- - |
- - |
- - |
| 2011 | -22.95% 54/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 长盛沪深300指数(LOF)A VS. 长安沪深300非周期A(740101) |